Marinomed Biotech AG | WebDisclosure

Switch to English

11189	Sociétés
247545	Mots-clés
175382	Articles
133771	Communiqués

Accueil
Sociétés
Marinomed Biotech AG

COMMUNIQUÉ DE PRESSE

publié le 16/07/2026 à 23:10, il y a 3 mois

EQS-Adhoc: Ad-hoc: Marinomed Biotech AG plans to apply for court restructuring proceedings without self-administration
Marinomed Biotech AG to apply for court restructuring proceedings without self-administration due to failed negotiations and insolvency risk. Aim to secure financial stability

Marinomed Biotech AG Financial Stability Insolvency Risk Restructuring Proceedings Court-approved Restructuring Plan
BRÈVE

publiée le 19/05/2026 à 08:03, il y a 4 mois 28 jours

Marinomed Biotech AG Forms Strategic Partnership for Marinosolv® in Inhalation Therapy

Strategic Partnership Biopharmaceuticals Respiratory Medicine Marinosolv® Technology Inhalation Therapy
BRÈVE

publiée le 19/05/2026 à 08:03, il y a 4 mois 28 jours

Marinomed Biotech AG conclut un partenariat stratégique pour Marinosolv® en thérapie par inhalation

Partenariat Stratégique Produits Biopharmaceutiques Pneumologie Technologie Marinosolv® Thérapie Par Inhalation
COMMUNIQUÉ DE PRESSE

publié le 19/05/2026 à 07:58, il y a 4 mois 28 jours

Marinomed Biotech AG Announces Strategic Partnership and Worldwide Licensing for Marinosolv® Technology in Inhalation Therapy
Marinomed Biotech AG partners with Phargentis SA for worldwide licensing of Marinosolv® Technology in Inhalation Therapy, offering advanced drug delivery solutions for respiratory medicine

Marinomed Biotech AG Drug Delivery Marinosolv® Technology Inhalation Therapy Phargentis SA
BRÈVE

publiée le 11/05/2026 à 11:14, il y a 5 mois 5 jours

Marinomed lance son collyre à base de tacrolimus sur le marché des préparations magistrales.

Marinomed Biotech AG Plateforme Marinosolv Collyre De Tacrolimus Marché À Effet Cumulatif Inflammation Oculaire
BRÈVE

publiée le 11/05/2026 à 11:14, il y a 5 mois 5 jours

Marinomed Advances Tacrolimus Eyedrops to Compounding Market

Marinomed Biotech AG Marinosolv Platform Tacrolimus Eyedrops Compounding Market Ocular Inflammation
COMMUNIQUÉ DE PRESSE

publié le 11/05/2026 à 11:09, il y a 5 mois 5 jours

Marinomed Biotech AG announces progress with Tacrolimus Eyedrops for Entry into the Compounding Market
Marinomed Biotech AG announces progress with Tacrolimus Eyedrops for Entry into the Compounding Market, targeting niche patient populations and high-need therapeutic areas with a strategic commercial milestone

Marinomed Biotech AG Marinosolv Technology Tacrolimus Eyedrops Compounding Market Ophthalmologists
BRÈVE

publiée le 22/04/2026 à 09:09, il y a 5 mois 24 jours

Marinomed Biotech AG Expands into Compounding Services

Global Expansion Marinomed Biotech Marinosolv Technology Compounding Services Customized Medicines
BRÈVE

publiée le 22/04/2026 à 09:09, il y a 5 mois 24 jours

Marinomed Biotech AG se développe dans le domaine des services de préparation magistrale

Expansion Mondiale Technologie Marinosolv Biotechnologie Marinomed Services De Préparation Magistrale Médicaments Personnalisés
COMMUNIQUÉ DE PRESSE

publié le 22/04/2026 à 09:04, il y a 5 mois 24 jours

Marinomed Announces Strategic Expansion into Compounding Services Featuring Marinosolv® Technology
Marinomed Biotech AG announces strategic expansion into compounding services with Marinosolv technology, offering personalized medicines for global demand

Marinomed Biotech AG Strategic Expansion Marinosolv Technology Compounding Services Personalized Medicines

Les Echos

Publié le 16/10/2026 à 19:54, il y a 10 heures 11 minutes

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 30 septembre 2026
Publié le 16/10/2026 à 18:48, il y a 11 heures 17 minutes

Disclosure of transactions in own shares from October 12 to October 16, 2026
Publié le 16/10/2026 à 18:48, il y a 11 heures 17 minutes

Déclaration hebdomadaire d'opérations effectuées du 12 au 16 octobre 2026
Publié le 16/10/2026 à 18:00, il y a 12 heures 6 minutes

KLARSEN : Compte rendu AGO et AGE du 8 octobre 2026
Publié le 16/10/2026 à 07:30, il y a 22 heures 36 minutes

Third Quarter Revenues 2026

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 17/10/2026 à 03:20, il y a 2 heures 46 minutes

Battery X Metals Highlights Participation at X Takeover 2026, an Electric Vehicle and Emerging Technology Event Held at Tesla's Gigafactory Texas, Providing Exposure to Industry Perspectives and Technology Developments
Publié le 17/10/2026 à 03:15, il y a 2 heures 51 minutes

Vanta Closes Second Tranche of Private Placement Financing and Welcomes Launch of First U.S.-Listed Peptide ETF, Highlighting Growing Recognition of Peptide Industry
Publié le 16/10/2026 à 23:35, il y a 6 heures 31 minutes

Initial Closing of US$3.4 Million Private Placement
Publié le 16/10/2026 à 23:30, il y a 6 heures 36 minutes

NiobiumX Mining Inc. Announces Retraction of Recent Marketing Materials
Publié le 16/10/2026 à 23:00, il y a 7 heures 6 minutes

Grid Announces Adoption of Advance Notice By-Law and Provides Shareholder Meeting Update

Voir tout ACCESSWIRE

EQS Group

Publié le 16/10/2026 à 20:08, il y a 9 heures 57 minutes

EQS-Adhoc: Rath AG // Rath Group reaches agreement with its key financial creditors on the terms of a transformation agreement and launches a transformation programme
Publié le 16/10/2026 à 19:20, il y a 10 heures 45 minutes

Arity to Acquire INRIX, Advancing a Connected Vision for the Future of Transportation
Publié le 16/10/2026 à 19:05, il y a 11 heures

Paris Court Ruling on Discontinued Feature Will Have Minimal Impact on Angelalign Customers
Publié le 16/10/2026 à 18:18, il y a 11 heures 47 minutes

Issue Price of Placing and WRAP Retail Offer
Publié le 16/10/2026 à 18:13, il y a 11 heures 52 minutes

EQS-Adhoc: DHL AG: DHL AG raises full-year 2026 earnings guidance